Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD

Bone Marrow Transplantation volume 50, pages 734–742 (2015)Cite this article

Subjects

Abstract

Steroid refractory acute GVHD (SR aGVHD) is associated with high morbidity and mortality. This study attempted to generate a risk model for SR aGVHD using 259 single nucleotide polymorphisms (SNPs) in 53 genes of recipients and donors. A total of 268 patients with aGVHD who were treated with systemic steroids were included. Patients were randomly divided into training (n=180) and validation sets (n=88). Clinical risk factors were also evaluated. In the training set, 85 (47.2%) developed SR aGVHD. Gastrointestinal involvement (P<0.0001) and donor genotypes of IL6 (rs1800797; P=6.2 × 10−4) and IFNG (rs2069727; P=4.4 × 10−4) were significant risk factors. Scores were assigned to the above risk factors. Patients were divided into low (score 0, n=74) vs high risk (scores 1–3; n=106) in risk model. Higher incidence of SR aGVHD was noted in the high risk (61.3%) vs the low-risk group (27%; P<0.0001, odds ratio (OR) 4.28). Predictive effect of risk model was replicated in the validation set (P=0.0045, OR 3.74). This risk model was associated with response to therapy, overall and GVHD-specific survival and non-relapse mortality. Our study suggested that this risk model could identify patients at high risk of SR aGVHD with donor genotype of IL6 (rs1800797) and IFNG (rs2069727) along with gastrointestinal involvement of aGVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024–1030.

    CAS  PubMed  Google Scholar 

  2. Martinez C, Solano C, Ferra C, Sampol A, Valcarcel D, Perez-Simon JA . Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. Biol Blood Marrow Transplant 2009; 15: 639–642.

    Article  CAS  PubMed  Google Scholar 

  3. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387–394.

    Article  CAS  PubMed  Google Scholar 

  4. Hings IM, Severson R, Filipovich AH, Blazar BR, Kersey JH, Ramsay NK et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 1994; 58: 437–442.

    Article  CAS  PubMed  Google Scholar 

  5. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol 2011; 2011: 601953.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013; 369: 529–539.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Arora M, Lindgren B, Basu S, Nagaraj S, Gross M, Weisdorf D et al. Polymorphisms in the base excision repair pathway and graft-versus-host disease. Leukemia 2010; 24: 1470–1475.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lee JC, Espeli M, Anderson CA, Linterman MA, Pocock JM, Williams NJ et al. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 2013; 155: 57–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Koumakis E, Bouaziz M, Dieude P, Ruiz B, Riemekasten G, Airo P et al. A regulatory variant in CCR6 is associated with anti-topoisomerase positive systemic sclerosis susceptibility. Arthritis Rheum 2013; 65: 3202–3208.

    Article  CAS  PubMed  Google Scholar 

  10. Xiang Q, Chen L, Fang J, Hou S, Wei L, Bai L et al. TNF receptor-associated factor 5 gene confers genetic predisposition to acute anterior uveitis and pediatric uveitis. Arthritis Res Ther 2013; 15: R113.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kim DD, Yun J, Won HH, Cheng L, Su J, Xu W et al. Multiple single-nucleotide polymorphism-based risk model for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease. Transplantation 2012; 94: 1250–1257.

    Article  CAS  PubMed  Google Scholar 

  12. Wermke M, Maiwald S, Schmelz R, Thiede C, Schetelig J, Ehninger G et al. Genetic variations of interleukin-23 R (1143 A&gt;G) and BPI (A645G), but not of NOD2, are associated with acute graft-versus-host disease after allogeneic transplantation. Biol Blood Marrow Transplant 2010; 16: 1718–1727.

    Article  CAS  PubMed  Google Scholar 

  13. Murphy N, Diviney M, Szer J, Bardy P, Grigg A, Hoyt R et al. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant 2006; 37: 773–779.

    Article  CAS  PubMed  Google Scholar 

  14. Viel DO, Tsuneto LT, Sossai CR, Lieber SR, Marques SB, Vigorito AC et al. IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Scand J Immunol 2007; 66: 703–710.

    Article  CAS  PubMed  Google Scholar 

  15. Ambruzova Z, Mrazek F, Raida L, Jindra P, Vidan-Jeras B, Faber E et al. Association of IL6 and CCL2 gene polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2009; 44: 227–235.

    Article  CAS  PubMed  Google Scholar 

  16. Kim DH, Jamal N, Saragosa R, Loach D, Wright J, Gupta V et al. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biol Blood Marrow Transplant 2007; 13: 1233–1243.

    Article  CAS  PubMed  Google Scholar 

  17. Kim DH, Kumar D, Messner HA, Minden M, Gupta V, Kuruvilla J et al. Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation. Clin Transplant 2008; 22: 770–779.

    Article  PubMed  Google Scholar 

  18. Siegal D, Keller A, Xu W, Bhuta S, Kim DH, Kuruvilla J et al. Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol Blood Marrow Transplant 2007; 13: 1369–1379.

    Article  PubMed  Google Scholar 

  19. Kim DH, Popradi G, Xu W, Gupta V, Kuruvilla J, Wright J et al. Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 471–482.

    Article  CAS  PubMed  Google Scholar 

  20. Alam N, Marras TK, Atenafu EG, Gupta V, Kuruvilla J, Lipton JH et al. Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versus-host disease of lung compared with bone marrow transplantation. Biol Blood Marrow Transplant 2012; 18: 1905–1910.

    Article  PubMed  Google Scholar 

  21. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    Google Scholar 

  22. EBMT-ESH HANDBOOK 2012.

  23. Parimon T, Au DH, Martin PJ, Chien JW . A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144: 407–414.

    Article  PubMed  Google Scholar 

  24. Lee KH, Choi SJ, Lee JH, Lee JS, Kim WK, Lee KB et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica 2005; 90: 939–948.

    PubMed  Google Scholar 

  25. Li Q, Zhai Z, Xu X, Shen Y, Zhang A, Sun Z et al. Decrease of CD4(+)CD25(+) regulatory T cells and TGF-beta at early immune reconstitution is associated to the onset and severity of graft-versus-host disease following allogeneic haematogenesis stem cell transplantation. Leuk Res 2010; 34: 1158–1168.

    Article  CAS  PubMed  Google Scholar 

  26. Shirasugi N, Aramaki O, Hatano M, Suda H, Tanaka K, Inoue F et al. Synergistic effect of 15-deoxyspergualin with costimulation blockade on alloimmune response. Transplant Proc 2004; 36: 2446–2447.

    Article  CAS  PubMed  Google Scholar 

  27. Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, Yakoub-Agha I . Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 2008; 42: 757–760.

    Article  CAS  PubMed  Google Scholar 

  28. Ochs LA, Blazar BR, Roy J, Rest EB, Weisdorf DJ . Cytokine expression in human cutaneous chronic graft-versus-host disease. Bone Marrow Transplant 1996; 17: 1085–1092.

    CAS  PubMed  Google Scholar 

  29. Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013; 48: 452–458.

    Article  CAS  PubMed  Google Scholar 

  30. Bowcock AM, Kidd JR, Lathrop GM, Daneshvar L, May LT, Ray A et al. The human ‘interferon-beta 2/hepatocyte stimulating factor/interleukin-6’ gene: DNA polymorphism studies and localization to chromosome 7p21. Genomics 1988; 3: 8–16.

    Article  CAS  PubMed  Google Scholar 

  31. Wine E, Mack DR, Hyams J, Otley AR, Markowitz J, Crandall WV et al. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. J Crohns Colitis 2013; 7: 916–922.

    Article  PubMed  Google Scholar 

  32. Bonifati C, Solmone M, Trento E, Pietravalle M, Fazio M, Ameglio F . Serum interleukin-6 levels as an early marker of therapeutic response to UVB radiation and topical steroids in psoriatic patients. Int J Clin Lab Res 1994; 24: 122–123.

    Article  CAS  PubMed  Google Scholar 

  33. Dittrich A, Khouri C, Sackett SD, Ehlting C, Bohmer O, Albrecht U et al. Glucocorticoids increase interleukin-6-dependent gene induction by interfering with the expression of the suppressor of cytokine signaling 3 feedback inhibitor. Hepatology 2012; 55: 256–266.

    Article  CAS  PubMed  Google Scholar 

  34. Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K et al. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. J Invest Dermatol 2012; 132: 2752–2761.

    Article  CAS  PubMed  Google Scholar 

  35. Dicarlo J, Agarwal-Hashmi R, Shah A, Kim P, Craveiro L, Killen R et al. Cytokine and chemokine patterns across one hundred days following hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 2014; 20: 361–369.

    Article  CAS  PubMed  Google Scholar 

  36. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369–1376.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Choi B, Lee DE, Park HY, Jeong S, Lee SM, Ji E et al. A meta-analysis of the effects of interleukin-6 -174 G&gt;C genetic polymorphism on acute graft-versus-host disease susceptibility. Clin Ther 2012; 34: 295–304.

    Article  CAS  PubMed  Google Scholar 

  38. Guichelaar T, Emmelot ME, Rozemuller H, Martini B, Groen RW, Storm G et al. Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells. Clin Cancer Res 2013; 19: 1467–1475.

    Article  CAS  PubMed  Google Scholar 

  39. Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009; 114: 891–900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Douglas Rizzo J, Saad A et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: 1862–1868.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Pawlik A, Czerny B, Dabrowska-Zamojcin E, Gornik W, Poziomkowska I, Gawronska-Szklarz B et al. [The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone]. Pol Arch Med Wewn 2005; 114: 843–847.

    PubMed  Google Scholar 

  42. Ruiz-Linares A . Dinucleotide repeat polymorphism in the interferon-gamma (IFNG) gene. Hum Mol Genet 1993; 2: 1508.

    Article  CAS  PubMed  Google Scholar 

  43. Sun K, Hsiao HH, Li M, Ames E, Bouchlaka M, Welniak LA et al. IFN-gamma receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation. J Immunol 2012; 189: 2033–2042.

    Article  CAS  PubMed  Google Scholar 

  44. Lu Y, Giver CR, Sharma A, Li JM, Darlak KA, Owens LM et al. IFN-gamma and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. Blood 2012; 119: 1075–1085.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Goleva E, Li LB, Leung DY . IFN-gamma reverses IL-2- and IL-4-mediated T-cell steroid resistance. Am J Respir cell Mol Biol 2009; 40: 223–230.

    Article  CAS  PubMed  Google Scholar 

  46. Lai HY, Chou TY, Tzeng CH, Lee OK . Cytokine profiles in various graft-versus-host disease target organs following hematopoietic stem cell transplantation. Cell Transplant 2012; 21: 2033–2045.

    Article  PubMed  Google Scholar 

  47. Das R, Komorowski R, Hessner MJ, Subramanian H, Huettner CS, Cua D et al. Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses. Blood 2010; 115: 5249–5258.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR . Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease. Blood 2009; 113: 2352–2362.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Burman AC, Banovic T, Kuns RD, Clouston AD, Stanley AC, Morris ES et al. IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood 2007; 110: 1064–1072.

    Article  CAS  PubMed  Google Scholar 

  50. McCandless EE, Rai SK, Mwangi D, Sly L, Franz LC . Hydrocortisone inhibits IFN-gamma production in equine, ovine, and bovine PBMCs. Vet Immunol Immunopathol 2013; 153: 128–133.

    Article  CAS  PubMed  Google Scholar 

  51. Li JJ, Wang W, Baines KJ, Bowden NA, Hansbro PM, Gibson PG et al. IL-27/IFN-gamma induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages. J Immunol 2010; 185: 4401–4409.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, Department of Medicine, Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada

    N Alam, J Uhm, M Seftel, V Gupta, J Kuruvilla, J H Lipton, H A Messner & D D H Kim

  2. Department of Biostatistics, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada

    W Xu & E G Atenafu

Authors
  1. N Alam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E G Atenafu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Uhm
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Seftel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Kuruvilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J H Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H A Messner
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D D H Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D D H Kim.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author Contributions

NA and DDHK contributed to the design of the study, supervision of data collection and data interpretation, data analysis and writing the manuscript. EGA and WX prepared statistical plan, performed statistical analysis and interpreted results. MS, VG, JU, JK, JHL and HAM were involved in the supervision of data collection and interpretation of the data. All authors critically reviewed and approved the final draft of the manuscript.

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alam, N., Xu, W., Atenafu, E. et al. Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD. Bone Marrow Transplant 50, 734–742 (2015). https://doi.org/10.1038/bmt.2015.19

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.19

This article is cited by

Search

Advanced search

Quick links